Health Awareness Topics - April 2012
New clinician and consumer guides added!
Visit the AHRQ Evidence Reports
page for a listing of reports produced under AHRQ's Evidence-based Practice Program
and Effective Health Care Program
The Guidelines International Network (G-I-N) Conference 2012
, will be held August 22-25, 2012
in Berlin, Germany. Registration
is now open.
U.S. Food and Drug Administration (FDA) Advisory
- April 20, 2012: Aliskiren-containing Medications : FDA notified healthcare professionals of possible risks when using blood pressure medicines containing aliskiren with other drugs called angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in patients with diabetes or kidney (renal) impairment. These drug combinations should not be used (are contraindicated) in patients with diabetes. In addition, avoid use of aliskiren with ARBs or ACEIs in patients with moderate to severe renal impairment. The labels for the aliskiren drugs are being updated based on preliminary data from a clinical trial
NGC's Sister Resources